腹腔镜肝切除术治疗原发性肝癌患者应用氢吗啡酮联合纳布啡静脉自控镇痛控制疼痛作用研究*

doi:10.3969/j.issn.1672-5069.2022.03.028

Abstract

Abstract: Objective The aim of this study was to investigate pain control by hydromorphone and nalbuphine combination for patient-controlled intravenous analgesia (PCIA) in patients with primary liver cancer (PLC) undergoing laparoscopic hepatectomy (LH). Methods 104 patients with PLC were encountered in our hospital between January 2018 and January 2021, and they were randomly divided into control (n=52) and observation group (n=52). All patients with PLC underwent LH, and the sufentanil and nalbuphine in patients in the control, while the hydromorphone and nalbuphine in patients in the observation for postoperative PCIA were applied. The T cell subsets, such as CD3⁺ cells, CD4⁺cells, CD8⁺ cells and NK cells, were detected by flow cytometry. The postoperative pain was assessed by visual analogue scale (VAS). Results At 24 h after surgery, the static and dynamic VAS scores in observation group were (2.5±0.8) points and (3.7±1.2) points, significantly lower than [(4.3±1.2) points and (5.8±1.7) points, P<0.05] in the control; at 72 h after surgery, the static and dynamic VAS scores in the observation group were (1.1±0.4) points and (3.2±0.9) points, significantly lower than [(2.6±0.7) points and (5.1±1.3) points, P<0.05] in the control; after surgery, there were no significant differences as respect to common liver function tests (P>0.05); at 7 d after surgery, the percentages of CD3⁺ cells, CD4⁺cells, CD8⁺ cells and NK cells in the observation group were (76.3±7.5)%,(36.8±4.9)%,(32.5±3.2)% and(16.3±2.9)%, all not significantly different as compared to [(75.2±7.4)%,(37.6±4.4)%,(31.2±3.4)% and (17.4±2.6)%] in the control (P>0.05). Conclusion The application of hydromorphone and nalbuphine combination in patients with PLC for PCIA after LH could effectively alleviate pain.

Key words: Hepatoma, Laparoscopic hepatectomy, Patient-controlled intravenous analgesia, Hydromorphone, Nalbuphine

Sun Hao, Cao Li, Cao Lin, et al. hydromorphone and nalbuphine combination for patient-controlled intravenous analgesia in patients with primary liver cancer undergoing laparoscopic hepatectomy[J]. Journal of Practical Hepatology, 2022, 25(3): 415-418.

References

[1] Polidoro MA, Mikulak J, Cazzetta V, et al. Tumor microenvironment in primary liver tumors: A challenging role of natural killer cells. World J Gastroenterol, 2020,26(33):4900-4918.
[2] Yang WS, Zeng XF, Liu ZN, et al. Diet and liver cancer risk: a narrative review of epidemiological evidence. Br JNutr, 2020,124(3):330-340.
[3] Shi JF, Cao M, Wang Y, et al. Is it possible to halve the incidence of liver cancer in China by 2050? Int J Cancer, 2021,148(5):1051-1065.
[4] Delvecchio A, Conticchio M, Ratti F, et al. Laparoscopic major hepatectomy for hepatocellular carcinoma in elderly patients: a multicentric propensity score based analysis. Surg Endosc, 2021,35(7):3642-3652.
[5] 吴丹,夏燕飞,杨晓明,等. 急性疼痛管理在胸科手术中镇痛的效果评价. 中华医学杂志,2020,100(38):3010-3013.
[6] Sato N, Satomi E, Yoshida T, et al. Hydromorphone incancer patients-a retrospective study. Gan To Kagaku Ryoho, 2020,47(12):1687-1690.
[7] 李涛,高晨,柴小青,等. 纳布啡PCIA对肝癌切除术患者术后细胞免疫功能的影响. 中华麻醉学杂志,2019,39(11):1357-1359.
[8] 中国抗癌协会肝癌专业委员会,中华医学会肝病学分会肝癌学组,中国抗癌协会病理专业委员会,等. 原发性肝癌规范化病理诊断指南(2015年版).中华肝胆外科杂志,2015,21(3):145-151.
[9] Rosas S,Paço M, Lemos C, et al. Comparison between the visual analog scale and the numerical rating scale in the perception of esthetics and pain. Int Orthod,2017,15(4):543-560.
[10] Sharma R. Descriptive epidemiology of incidence and mortality of primary liver cancer in 185 countries: evidence from GLOBOCAN 2018.Jpn J Clin Oncol, 2020,50(12):1370-1379.
[11] Yang WS, Zeng XF, Liu ZN, et al. Diet and liver cancer risk: a narrative review of epidemiological evidence. Br JNutr, 2020,124(3):330-340.
[12] Yoshida H,Taniai N, Yoshioka M, et al. Current status of laparoscopic hepatectomy. J Nippon Med Sch,2019,86(4):201-206.
[13] Egger ME,Gottumukkala V, Wilks JA, et al. Anesthetic and operative considerations for laparoscopic liver resection. Surgery,2017,161(5):1191-1202.
[14] Katz P,Takyar S, Palmer P, et al. Sublingual, transdermal and intravenous patient-controlled analgesia for acute post-operative pain: systematic literature review and mixed treatment comparison. Curr Med Res Opin, 2017,33(5):899-910.
[15] Han L, Su Y,Xiong H, et al. Oxycodone versus sufentanil in adult patient-controlled intravenous analgesia after abdominal surgery: A prospective, randomized, double-blinded, multiple-center clinical trial. Medicine (Baltimore),201,97(31):11552-11565.
[16] Rakowski JA, Holloway RW, Ahmad S, et al. A prospective randomized trial of intravenous ketorolac vs. acetaminophen administered with opioid patient-controlled analgesia in gynecologic surgery.Gynecol Oncol,2019,155(3):468-472.
[17] Zhang Y, Zhang R, Ding N. Investigation of analgesic dose of nalbuphine combined with remifentanil after radical gastrectomy.Exp Ther Med, 2019,18(3):1633-1638.
[18] Raghav R, Jain R, Dhawan A, et al. Chronic co-administration of nalbuphine attenuates the development of opioid dependence.Pharmacol Biochem Behav,2018,175(1):130-138.
[19] Lee W, Gao X, Tang J,et al. Postoperative sufentanil intravenous patient-controlled analgesia within the first 24 hours: a retrospective study. Ann Palliat Med,2020,9(6):3932-3937.
[20] Sridharan K, Sivaramakrishnan G. Comparison of fentanyl, remifentanil, sufentanil and alfentanil in combination with propofol for general anesthesia: a systematic review and meta-analysis of randomized controlled Trials. Curr Clin Pharmacol,2019,14(2):116-124.
[21] Riba P, Tóth Z, Hosztafi S, et al. Effects of structural modifications of N-CPM-normorphine derivatives on agonist and antagonist activities in isolated organs. Acta Biol Hung,2019,54(2):177-181.
[22] Rodrigues S, Shin D, Conway M, et al. Hydromorphone versus morphine: a historical cohort study to evaluate the quality of postoperative analgesia. Can J Anaesth,2021,68(2):226-234.
[23] 范倩倩,计根林,聂煌,等. 氢吗啡酮联合纳布啡用于胃肠道手术后PCIA的效果. 中华麻醉学杂志,2020,40(12):1471-1474.
[24] Robles-Diaz M, Garcia-Cortes M, Medina-Caliz I, et al. The value of serum aspartate aminotransferase and gamma-glutamyl transpetidase as biomarkers in hepatotoxicity. Liver Int,2015,35(11):2474-2482.
[25] Sung PS, Jang JW. Naturalkiller cell dysfunction in hepatocellular carcinoma: pathogenesis and clinical implications. Int J Mol Sci,2018,19(11):3648-3652.
[26] Garnelo M, Tan A, Her Z, et al. Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma. Gut, 2017,66(2):342-351.
[27] Zheng B, Wang D, Qiu X, et al. Trajectory and functional analysis of PD-1 high CD4⁺CD8⁺ T cells in hepatocellular carcinoma by single-cell cytometry and transcriptome sequencing. Adv Sci (Weinh),2020,7(13):20224-20236.
[28] Ma B, Liu X, Yu Z. The effect of high intensity focused ultrasound on the treatment of liver cancer and patients' immunity. Cancer Biomark,2019,24(1):85-90.
[29] 李涛, 高晨, 柴小青,等. 纳布啡PCIA对肝癌切除术患者术后细胞免疫功能的影响.中华麻醉学杂志,2019,39(11):1357-1359.
[30] Berkowitz BA,Ceretta KV, Spector S. Influence of active and passive immunity on the disposition of dihydromorphine-H3. Life Sci,2017,15(5):1017-28.

hydromorphone and nalbuphine combination for patient-controlled intravenous analgesia in patients with primary liver cancer undergoing laparoscopic hepatectomy

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Hu Yongjun, Wang Lei, Liu Ning, et al. Strategy of intermittent total hepatic inflow occlusion and regional hepatic inflow occlusion during laparoscopic hepatectomy in patients with primary liver cancer [J]. Journal of Practical Hepatology, 2022, 25(3): 411-414.
[2]	Qiu Yun, Yang Mei, Xue Honghong. Clinical efficacy of ultrasound-guided microwave ablation after TACE in treatment of patients with special locations of primary liver cancer [J]. Journal of Practical Hepatology, 2022, 25(3): 419-422.
[3]	Liu Huimin, Liu Xiaoli, Wang Xinhui, et al. Implication of peripheral CD4+T, CD8+T, Tc17, Th17 and Treg lymphocyte changes in patients with primary liver cancer [J]. Journal of Practical Hepatology, 2022, 25(2): 255-258.
[4]	Wang Chan, Shen Changqing, Wu Xiaoqiong, et al. Efficacy and safety of epirubicin drug-eluting beads-transcatheter arterial chemoembolization in the treatment of patients with unresectable primary liver cancer [J]. Journal of Practical Hepatology, 2022, 25(2): 259-262.
[5]	Wang Xinran, Jiang Yandong, Zhang Meng. Local control of tumors in patients with hepatocellular carcinoma receiving ultrasound-guided intratumorous125I radioactive particle implantation [J]. Journal of Practical Hepatology, 2022, 25(2): 263-266.
[6]	Wang Lianshuang, Zhang Yao, Shan Tao, et al. Ultrasonographic feature and prognosis of patients with hepatocellular carcinaoma and cardiac metastases: Analysis of 19 cases [J]. Journal of Practical Hepatology, 2022, 25(2): 271-274.
[7]	Li Huan, Li Yang, Du Juan, et al. Cancerous expression and functional relations of glypican3 and sonic Hedgehog proteins in patients with hepatocellular carcinoma and in hepatoma cell lines in vitro [J]. Journal of Practical Hepatology, 2022, 25(1): 83-87.
[8]	Peng Nan, Ma Aizhen, Shi Zhan, et al. Application of CT 3D reconstruction in the evaluation of resectability of massive intrahepatic tumors in patients with primary liver cancer [J]. Journal of Practical Hepatology, 2022, 25(1): 96-99.
[9]	Zhou Yan, Li Guoping, Deng Jun, et al. Efficacy of thymosin alpha 1 in maintained treatment of patients with primary liver cancer after radiofrequency ablation [J]. Journal of Practical Hepatology, 2021, 24(6): 907-910.
[10]	Zhou Zheng, Liu Wei. Contrast-enhanced ultrasound features of hepatic hemangioma, hepatocellular carcinoma and hepatic angiomyolipoma [J]. Journal of Practical Hepatology, 2021, 24(6): 911-914.
[11]	Zhao Pengfei, Zu Hongmei, Xin Xiaoen, et al. Logistic regression analysis of risk factors in patients with hepatocellular carcinoma [J]. Journal of Practical Hepatology, 2021, 24(6): 927-929.
[12]	Peng Guangming, Ge Shang, Jin Guiyin. Image quality of adaptive statistical iterative reconstruction under low tube voltage of CT scan in diagnosis of patients with primary liver cancer [J]. Journal of Practical Hepatology, 2021, 24(5): 737-740.
[13]	Yu Lei, Sun Chao, Zhang Manxu. Regulation of intestinal floras and their metabolism functions by ganoderma lucidum plysaceharide in mice with HepG2 cell-induced implanted cancer [J]. Journal of Practical Hepatology, 2021, 24(4): 476-479.
[14]	Chen Wei, Wei Tao, Yang Lan, et al. Expression of NLRP3 inflammasome in cancerous tissues of patients with primary liver cancer [J]. Journal of Practical Hepatology, 2021, 24(4): 544-547.
[15]	Liu Yongchang, Zhao Diantang, Sun Qifeng, et al. Application of indocyanine green fluorescence navigationand three-dimensional visualization in laparoscopic precision surgery for patients with primary liver cancer [J]. Journal of Practical Hepatology, 2021, 24(4): 561-564.